Nanotechnology Now - Press Release: "In 2015, Nanoparticle Paclitaxel in Combination with Carboplatin Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for First-Line Advanced Squamous Non-Small-Cell Lung Cancer"

Home > Press > In 2015, Nanoparticle Paclitaxel in Combination with Carboplatin Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for First-Line Advanced Squamous Non-Small-Cell Lung Cancer

Abstract:
The Overall Non-Small-Cell Lung Cancer Drug Market Will Expand from $4.2 Billion in 2010 to $5.4 Billion in 2020, According to Findings from Decision Resources

In 2015, Nanoparticle Paclitaxel in Combination with Carboplatin Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for First-Line Advanced Squamous Non-Small-Cell Lung Cancer

Burlington, MA | Posted on March 29th, 2012

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, nanoparticle paclitaxel (Celgene's Abraxane) in combination with carboplatin (Bristol-Myers Squibb's Paraplatin, generics) will earn Decision Resources' proprietary clinical gold standard status for first-line advanced squamous non-small-cell lung cancer in 2015, following its launch for the indication in 2012. Owing to its competitive advantages in efficacy, nanoparticle paclitaxel in combination with carboplatin will displace Decision Resources' current proprietary clinical gold standard, gemcitabine (Eli Lilly's Gemzar, generics) plus carboplatin.

Decision Resources' analysis of the non-small-cell lung cancer drug market also finds that surveyed U.S. oncologists and managed care organization (MCO) pharmacy directors agree that increased overall survival is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in first-line advanced squamous non-small-cell lung cancer. Clinical data and interviewed thought leaders indicate that nanoparticle paclitaxel in combination with carboplatin, ipilimumab (Bristol-Myers Squibb's Yervoy) in combination with paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin, and necitumumab (ImClone Systems/Bristol-Myers Squibb) in combination with gemcitabine/cisplatin* have advantages on this attribute over sales-leading gemcitabine/carboplatin.

The findings also reveal that, despite the generic erosion of numerous key agents that treat the disease, the non-small-cell lung cancer drug market will expand from $4.2 billion in 2010 to $5.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, drug sales for metastatic/advanced squamous cell non-small-cell lung cancer, which comprises only a small fraction of the market, will decrease from nearly 17 percent in 2010 to approximately 13 percent in 2020.

"Notably, sales of Eli Lilly's Alimta and Genentech/OSI Pharmaceuticals/Roche/Chugai Pharmaceutical's Tarceva—two branded agents that are prescribed principally to patients with non-squamous cell histology and dominated the non-small-cell lung cancer space in 2010—will weaken from 2015 to 2020," said Decision Resources Analyst Karen Pomeranz, Ph.D.

According to surveyed U.S. oncologists and MCO pharmacy directors, increasing overall survival is one of the greatest unmet needs in first-line advanced squamous non-small-cell lung cancer. Clinical data and interviewed thought leaders indicate that nanoparticle paclitaxel/carboplatin, ipilimumab in combination with paclitaxel/carboplatin, and necitumumab in combination with gemcitabine/cisplatin have demonstrated the potential to partially fulfill this unmet need.

*Cisplatin (Bristol-Myers Squibb's Platinol-AQ/Briplatin, Pfizer's Platosin, OSI Pharmaceuticals/Nippon Kayaku's Randa, generics).

Decision Resources' Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series.

####

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, please click here

Contacts:
Decision Resources
Christopher Comfort, 781-993-2597

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: